Pharmaceuticals
Swiss multinational pharmaceutical company (SIX: NOVN; NYSE: NVS). Focused on innovative medicines in oncology, cardiovascular, immunology, and neuroscience. $45bn revenue 2023. 78,000+ employees. Novartis Thailand manages innovative-medicines portfolio plus Novartis Access emerging-market programme.
Composite score across 5 categories MNCs operating in Thailand can demonstrate.
How this is computed: a weighted average of 5 sub-scores. Higher weight on signals an MNC has agency over (Thailand venue depth, international disclosure framework adoption, DEI policy explicitness) and lower weight on audit / scale signals that depend on company size.
How Novartis AGis showing up for Thailand's LGBTQ+ community
Inclusion Dividend
Not yet enrolled
Creator partners
0
verified Thai KOLs
Audit history
No audit yet
Thailand presence
Single market presence
PrideShow LGBTQ+ ESG score (global) — Thailand-specific signals are above
86
Platinum · A+
LGBTQ+ Policy
100
Supply Chain
75
Community
70
Reporting
100
HRC Corporate Equality Index 100% score (US ops)
2023 Novartis in Society Integrated Report — GRI / TCFD / CDP / SASB aligned
CDP Climate A-List
DJSI World + Europe + FTSE4Good Index constituent
Bloomberg Gender-Equality Index constituent
Novartis Pride — global LGBTQ+ ERG
Novartis Access — low-cost medicine basket for LMICs
Signatory to UN Global Compact
Net-zero across value chain by 2040 commitment
Access to Medicines Index top-5
Patient Engagement Program — LGBTQ+ healthcare research
Reach Novartis AG's Thailand and APAC teams through PrideShow. Whether you're an NGO with a partnership idea, an SME on the supplier path, or a fellow MNC exploring co-activation — start the conversation here.
Is this your company?
Claim the listing to manage your Thailand inclusion evidence, respond to inbound enquiries, and connect with NGO and creator partners. Or sponsor PrideShow 2026 directly.
